In vitro fluconazole and voriconazole susceptibilities of candida bloodstream isolates in korea: Use of the CLSI and EUCAST epidemiological cutoff values

Annals of Laboratory Medicine

Volumn 33, Issue 3, 2013, Pages 167-173

  Jang, Min Joong ^a   Shin, Jong Hee ^a   Lee, Wee Gyo ^b   Kim, Mi Na ^c   Lee, Kyungwon ^d   Lee, Hye Soo ^e   Lee, Mi Kyung ^f   Chang, Chulhun L ^g   Jang, Hee Chang ^a   Song, Eun Song ^a   Kim, Soo Hyun ^a   Shin, Myung Geun ^a   Suh, Soon Pal ^a   Ryang, Dong Wook ^a  

^a Chonnam National University Medical School   (South Korea)

^b Ajou University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Chonbuk National University Medical School   (South Korea)

^f Chung Ang University College of Medicine   (South Korea)

^g Pusan National University School of Medicine   (South Korea)

Author keywords

Candida; CLSI; Epidemiological cutoff value; EUCAST; Fluconazole; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SOUTH KOREA;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REPUBLIC OF KOREA; TRIAZOLES; VORICONAZOLE;

EID: 84877960326     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2013.33.3.167     Document Type: Article

References (19)

1. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wildtype MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010;13:180-95.
2. Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011;70:330-43.
3. Pfaller MA and Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012;50: 2846-56.
4. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. 3rd ed, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
5. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14:398-405.
6. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing. EUCAST technical note on fluconazole. Clin Microbiol Infect 2008;14:193-5.
7. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing. EUCAST technical note on voriconazole. Clin Microbiol Infect 2008;14:985-7.
8. Rambach G, Oberhauser H, Speth C, Lass-Flörl C. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Med Mycol 2011;49:856-63.
9. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011;49:3800-4.
10. Jung SI, Shin JH, Song JH, Peck KR, Lee K, Kim MN, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol 2010;48:669-74
11. Pfaller MA and Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;10: S11-23.
12. Pfaller MA and Diekema DJ. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr Fungal Infect Rep 2010;4:168-74.
13. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66.
14. Pfaller MA, Espinel-Ingroff A, Boyken L, Hollis RJ, Kroeger J, Messer SA, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011;49:845-50.
15. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010;67:162-71.
16. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45
17. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009;47: 296-304.
18. Shin JH, Chae MJ, Song JW, Jung SI, Cho D, Kee SJ, et al. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol 2007; 45:2385-91.
19. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005;49:668-79.